Repligen Corp. of Cambridge, Mass., has entered into a new areaby licensing from the University of Michigan monoclonalantibody-based technology with potential anti-inflammatoryapplications. The antibodies bind to a white blood cell adhesionmolecule, thus preventing the migration of inflammatory cellsfrom the blood and subsequent tissue damage. The company(NASDAQ: RGEN) also announced that its AIDS vaccine partner,Merck & Co., has licensed a technology from MedImmune Inc.of Gaithersburg, Md., that may improve the vaccine.MedImmune has developed a method for inserting HIV genesinto a non-pathogenic bacterium, thus creating a living vaccinethat stimulates a cellular immune response as well as anantibody response.
(c) 1997 American Health Consultants. All rights reserved.